Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published1

Jena, Germany | 26 August 2020 | Carl Zeiss Meditec AG

Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). Within the accuracy of the study, the risk of a local tumor recurrence in the breast is similar and non-breast cancer death is reduced. The TARGIT-A randomized, multi-center phase 3 study involving 2298 patients with a median patient follow-up time of 8.6 years meets the highest scientific standards.

Globally more than 40,000 patients have already been treated, in over 350 breast cancer centers, with the TARGIT method. "Single dose intra-operative radiotherapy for early stage breast cancer can be a better alternative to conventional whole breast radiotherapy for most patients during primary tumor management " stated the principal investigator Professor Jayant Vaidya, Professor of Surgery and Oncology and Scientific Director at University College London when presenting the results of the study. “These excellent results provide real clinical justification for single intraoperative radiation in suitable patients with early breast cancer. It is now essential to develop the corresponding treatment guidelines as soon as possible”, added Professor Jeffrey Tobias, Professor of Oncology at University College London and joint initiator of the TARGIT-A study.

Positive clinical study results validate TARGIT as an option in breast cancer treatment

The local, recurrence-free survival rate of women treated with single dose TARGIT is non-inferior when compared with EBRT. The mortality in the TARGIT arm was even lower because of fewer cardio-vascular deaths.

"We are delighted with the positive results, as the ZEISS INTRABEAM 600 now represents an outstanding treatment alternative for many patients. We are confident that the procedure can now find its way into everyday clinical practice" said Ludwin Monz, CEO of Carl Zeiss Meditec AG.

TARGIT method underscored as an efficiency-oriented treatment

"This study reflects two decades of interdisciplinary clinical research by leading radiation oncologists, surgeons, physicists and health economists. The TARGIT-A trial has offered many breast cancer patients a treatment that is well tolerated, effective, convenient and highly cost efficient", summarized Professor William Small, Professor of Radio-oncology at Loyola University, Chicago and one of the world's leading radiation oncologists.

 

1 https://www.bmj.com/content/370/bmj.m2836

Press Contact

Petra Rettenmaier
Head of Marketing Communications Visualization
Carl Zeiss Meditec AG
Phone: +49 7364 204-232
press .meditec @zeiss .com

Investor Relations Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med
 

Press Contact

Petra Rettenmaier
Head of Marketing Communications Visualization
Carl Zeiss Meditec AG
Phone: +49 7364 204-232
press .meditec @zeiss .com

Investor Relations Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Further Articles

ZEISS Medical Technology Nominated for Deutscher Zukunftspreis 2020

Improving medicine through robotics and multi-layered augmentation

ZEISS experts Dr.-Ing. Michelangelo Masini and Frank Seitzinger represent the ZEISS team and, together with Prof. Dr....

Sep 8, 2020

ZEISS IOLMaster 700 Software Update 1.90 With Central Topography

ZEISS IOLMaster software update enables greater cataract workflow efficiency to support better outcomes for surgeons and patients.

ZEISS IOLMaster 700 Software Update 1.90 With Central Topography ZEISS IOLMaster software update enables greater cata...

Aug 26, 2020

Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published

Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirme...

Aug 25, 2020